Skip to main content
. 2021 Dec 1;228:114030. doi: 10.1016/j.ejmech.2021.114030

Fig. 3.

Fig. 3

Rational design of SARS-CoV-2 3CLpro inhibitors by privileged scaffold fusion and structure-activity relationships study.